Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
Shekoufeh Nikfar, Abbas Kebriaeezadeh, Rassoul Dinarvand, Mohammad Abdollahi, Mohammad Ali Sahraian, David Henry, Ali Akbari Sari*
*Corresponding author for this work
Research output: Contribution to journal › Article › Research › peer-review
Dive into the research topics of 'Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments'. Together they form a unique fingerprint.